The Association between Treatment for Metabolic Disorders and Breast Cancer Characteristics

Table 1

Tumor burden and Oncotype DX recurrence score.

Population ()			⁢Macroscopic; ⁢node positive^1		Stage (%)				Oncotype Dx RS
	Mean size cm (SD)		(%)		I	II	III		Mean (SD)
All (671)	1.67 (0.79)	—	9	—	71.2	28.3	0.5	—	19.06 (10.27)	—
Metformin^3 (60)	1.72 (0.79)	0.621	13.3	0.217	65	35	0	0.89	16.4 (8.52)	0.035
Insulin^3 (9)	2.03 (0.6)	0.171	11.1	0.574	44.4	55.6	0	0.727	17.67 (13.64)	0.682
Statins^3 (208)	1.77 (0.95)	0.067	9.2	0.994	67	32.5	0.5	0.226	18.11 (10.3)	0.108
Levothyroxine^3 (62)	1.61 (0.68)	0.509	6.5	0.464	69.4	30.6	0	0.949	17.1 (8.35)	0.062

¹Macroscopic nodes-lymph node metastases > 2 millimeter.
² value refers to comparison of each variable between patients who used the specified medication to the rest of the cohort.
Medication usage was not available for 15 patients.
RS: recurrence score.
³Median duration of medications usage (months, range): metformin 50.5 (1–80.5), insulin 56 (10–126), statins 72 (1–168), and levothyroxine 113 (8–168).